Cel-Sci Corporation

CVM Healthcare Biotechnology

In the quarter to June 2026, EPS grew 65.4%, free cash flow fell 2.33% and total debt fell 39.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

1.79 0.05 +2.87%
Market cap
$30.6M
P/E
0.0×
Fwd P/E
−12.2×
Dividend yield
—
F-score
4/9
Altman Z
−1.64
Beneish M
−2.35
Dividend safety
n/a
Sep '25 Sep '24 Sep '23 Sep '22 Sep '21 Sep '20 Sep '19 Sep '18 Sep '17 Sep '16
Piotroski F-Score
— — — — — 4 — — — —
P/E ratio
— — — — — 0.00 0.00 0.00 — 0.00
P/S ratio
— — — — — 838.05 601.73 151.85 — 132.11
Altman Z-Score
— — — — — (1.64) (12.60) (16.06) — (18.23)
Altman Z″-Score (non-manufacturers)
— — — — — (32.34) (44.81) (39.86) — (43.42)
P/FCF ratio
— — — — — 0.00 0.00 0.00 — 0.00
Beneish M-Score
— — — — — (2.35) (3.55) — — 7.88
P/Operating CF
— — — — — (130.56) (71.63) (17.05) — (5.49)
P/B ratio
— — — — — 23.74 54.23 80,414.60 — 0.00
EV/Sales
— — — — — 833.24 615.05 160.61 — 171.39
EV/EBITDA
— — — — — 0.00 0.00 0.00 — 0.00
EV/FCF
— — — — — (25.90) (17.09) (5.69) — (2.11)
Current Ratio
2.26 1.31 1.24 5.45 11.50 4.15 3.25 1.24 0.39 1.36
Net Debt/EBITDA
0.25 (0.14) (0.21) 0.34 0.85 0.14 (0.26) (0.22) (0.55) (0.44)
Debt/Equity
0.36 0.62 0.75 0.36 0.23 0.60 2.63 14,866.67 (3.96) (19.16)
ROE
(176.32%) (211.49%) (142.65%) (84.85%) (96.28%) (243.58%) (862.17%) 1,909.51% 718.45% 423.14%
ROA
(92.16%) (95.90%) (79.86%) (59.54%) (63.08%) (88.84%) (77.38%) (121.31%) (60.35%) (43.09%)
ROIC
(145.08%) (102.38%) (103.44%) (106.25%) (82.04%) (113.43%) (123.78%) (341.36%) (178.26%) (157.00%)
Return on Tangible Assets
(202.56%) (288.20%) (280.94%) (115.21%) (66.75%) (157.07%) (97.85%) (172.82%) (141.64%) (61.25%)
Average Days of Receivables
— — — — 0.00 35.87 49.53 90.91 0.00 505.06
Earnings Yield
— — — — — (6.44%) (7.61%) (44.65%) — (29.06%)
Free Cash Flow Yield
— — — — — (3.84%) (5.98%) (18.58%) — (61.42%)
Free Cash Flow per Share
(4.23) (10.50) (15.68) (13.15) (20.55) (14.68) (16.05) (23.75) (52.55) (142.70)
Book value per Share
3.93 7.14 8.92 22.38 41.75 16.12 4.95 0.00 (12.70) (4.19)
Free Cash Flow
(17.16) (18.92) (23.22) (18.90) (27.83) (17.97) (16.66) (13.45) (13.81) (23.12)
EV/EBIT
— — — — — 0.00 0.00 0.00 — 0.00
Other line items

Show all line items

Columns are period end dates